BRAF and neoplasm: Upon progression, BRAF inhibitor‐related, positive immunoregulatory effects are cleared, suggesting that BRAF inhibitor resistance is associated with an immunosuppressed tumor microenvironment, potentially contributing to a lack of response to subsequent anti‐PD‐1 therapy (Frederick et al., 2013).